Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c
August 5, 2021 4:28 PM EDTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.
We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is... More
